Cargando…

Assessment of efficacy and tolerability of once-daily extended release metformin in patients with type 2 diabetes mellitus

AIMS: To determine prospectively the efficacy, tolerability and patient satisfaction of an extended release formulation of metformin (metformin XR) in hospital based outpatients with type 2 diabetes mellitus currently treated with standard metformin. METHODS: Patients on immediate release standard m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Levy, Juliana, Cobas, Roberta A, Gomes, Marília B
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2847989/ https://www.ncbi.nlm.nih.gov/pubmed/20298568 http://dx.doi.org/10.1186/1758-5996-2-16

Ejemplares similares

Correction: Assessment of efficacy and tolerability of once-daily extended release metformin in patients with type 2 diabetes mellitus
por: Levy, Juliana, et al.
Publicado: (2010)

Post-transplant diabetes mellitus
por: Gomes, Marília B, et al.
Publicado: (2009)

Adding Saxagliptin to Metformin Extended Release (XR) or Uptitration of Metformin XR: Efficacy on Daily Glucose Measures
por: Neutel, Joel M., et al.
Publicado: (2013)

Increased functional and structural skin capillary density in type 1 diabetes patients with vascular complications
por: Tibiriçá, Eduardo, et al.
Publicado: (2009)

Twice-Daily versus Once-Daily Pramipexole Extended Release Dosage Regimens in Parkinson's Disease
por: Yun, Ji Young, et al.
Publicado: (2017)

Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin
por: Kapitza, C, et al.
Publicado: (2013)

Formulation and Evaluation of Once Daily Minocycline Hydrochloride Extended Release Matrix Tablets
por: Keny, R. V., et al.
Publicado: (2009)

Maintaining remission in ulcerative colitis – role of once daily extended-release mesalamine
por: Oliveira, Lilliana, et al.
Publicado: (2011)

Effects of Renal Impairment on the Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets
por: deVries, Tina, et al.
Publicado: (2019)

The Effect of Once-Daily Gabapentin Extended Release Formulation in Patients With Postamputation Pain
por: Knezevic, Nebojsa Nick, et al.
Publicado: (2019)

Model‐Informed Development and Registration of a Once‐Daily Regimen of Extended‐Release Tofacitinib
por: Lamba, M, et al.
Publicado: (2017)

A prospective cohort conversion study of twice-daily to once-daily extended-release tacrolimus: role of ethnicity
por: Glick, Lauren, et al.
Publicado: (2014)

Effectiveness and gastrointestinal tolerability during conversion and titration with once-daily OROS® hydromorphone extended release in opioid-tolerant patients with chronic low back pain
por: Hale, Martin E, et al.
Publicado: (2013)

Extended‐Release Once‐Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate‐Release Tofacitinib and Impact of Food
por: Lamba, Manisha, et al.
Publicado: (2016)

Pharmacokinetics of Once‐Daily Extended‐Release Tacrolimus Tablets Versus Twice‐Daily Capsules in De Novo Liver Transplant
por: DuBay, Derek A., et al.
Publicado: (2019)

Intranasal Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users
por: Harris, Stephen C., et al.
Publicado: (2016)

Oral Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users
por: Harris, Stephen C., et al.
Publicado: (2017)

Effectiveness and Safety of Once-Daily Extended-Release Hydrocodone in Individuals Previously Receiving Immediate-Release Oxycodone for Chronic Pain
por: Pergolizzi, Joseph, et al.
Publicado: (2018)

Conversion From Twice-Daily Tacrolimus to Once-Daily Extended Release Tacrolimus (LCPT): The Phase III Randomized MELT Trial
por: Bunnapradist, S, et al.
Publicado: (2013)

Clinical utility and consumer considerations for the use of once-daily nevirapine extended release for HIV infection treatment
por: Yone, Eric W Pefura, et al.
Publicado: (2012)

Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia
por: Hauser, Robert A., et al.
Publicado: (2018)

Safety, tolerability, and efficacy of metformin extended-release oral antidiabetic therapy in patients with type 2 diabetes: An observational trial in Asia
por: Kim, Chul-Hee, et al.
Publicado: (2012)

Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus
por: Petersen, Andreas B, et al.
Publicado: (2013)

Comparative efficacy and safety profile of once-weekly Semaglutide versus once-daily Sitagliptin as an add-on to metformin in patients with type 2 diabetes: a systematic review and meta-analysis
por: Patel, Tirath, et al.
Publicado: (2023)

Efficacy and safety of switching from nevirapine immediate-release twice daily to nevirapine extended-release once daily in virologically suppressed HIV-infected patients: a retrospective cohort study in Taiwan
por: Lee, Chun-Yuan, et al.
Publicado: (2017)

Efficacy and Safety of Lixisenatide Once-Daily Morning or Evening Injections in Type 2 Diabetes Inadequately Controlled on Metformin (GetGoal-M)
por: Ahrén, Bo, et al.
Publicado: (2013)

Effects of once-daily extended release quetiapine fumarate on patient-reported outcomes in patients with generalized anxiety disorder
por: Endicott, Jean, et al.
Publicado: (2012)

The efficacy and safety of once-daily quetiapine extended release in patients with schizophrenia switched from other antipsychotics: an open-label study in Chinese population
por: Pan, Pei-Yin, et al.
Publicado: (2015)

Real-World Study of Once-Daily, Extended-Release Tacrolimus Versus Twice-Daily, Immediate-Release Tacrolimus in Kidney Transplantation: Clinical Outcomes and Healthcare Resource Utilization
por: Ho, Bing, et al.
Publicado: (2019)

Efficacy and safety of exenatide once‐weekly vs exenatide twice‐daily in Asian patients with type 2 diabetes mellitus
por: Ji, Linong, et al.
Publicado: (2013)

Once-Daily Tacrolimus Extended-Release Formulation: 1 Year after Conversion in Stable Pediatric Kidney Transplant Recipients
por: Pape, Lars, et al.
Publicado: (2011)

Evaluation of Flexible Tacrolimus Drug Concentration Monitoring Approach in Patients Receiving Extended‐Release Once‐Daily Tacrolimus Tablets
por: Philosophe, Benjamin, et al.
Publicado: (2018)

Efficacy and Safety of Linagliptin Co-Administered with Low-Dose Metformin Once Daily Versus High-Dose Metformin Twice Daily in Treatment-Naïve Patients with Type 2 Diabetes: a Double-Blind Randomized Trial
por: Ji, Linong, et al.
Publicado: (2015)

Predicted Efficacy of Once-Daily Extended-Release Oxcarbazepine (Oxtellar XR(®)) Monotherapy in Adults and Children with Partial-Onset Seizures: Exposure-Response Modeling and Simulation
por: Faison, Shamia, et al.
Publicado: (2020)

Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes
por: Mann, Katherine V, et al.
Publicado: (2014)

Once-Weekly Exenatide Versus Once- or Twice-Daily Insulin Detemir: Randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas
por: Davies, Melanie, et al.
Publicado: (2013)

A review of glycemic efficacy of liraglutide once daily in achieving glycated hemoglobin targets compared with exenatide twice daily, or sitagliptin once daily in the treatment of type 2 diabetes
por: Alshali, Khalid Z., et al.
Publicado: (2016)

Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes
por: Wysham, Carol H., et al.
Publicado: (2017)

Potential benefit of dolutegravir once daily: efficacy and safety
por: Fantauzzi, Alessandra, et al.
Publicado: (2013)

Comparison of the Effectiveness of Once-Daily Alogliptin/Metformin and Twice-Daily Anagliptin/Metformin Combination Tablet in a Randomized, Parallel-Group, Open-Label Trial in Japanese Patients with Type 2 Diabetes
por: Yamazaki, Shunsuke, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o12rvppie4391ujra6h2b5lu18